Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs Psilocybin

Is psychedelic-assisted psychotherapy for depression more cost-effective than conventional treatments?

by Laura Staloch
August 18, 2023
in Psilocybin
Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

Researchers in the United Kingdom recently conducted a study to determine if psychedelic-assisted psychotherapy could be a more cost-effective option than more traditional forms of psychotherapy for those who experience depression. The results suggested that this unique approach could be a cost-effective choice, but only under certain circumstances. The research was published in the journal Psychological Medicine.

Depression is a widespread mental health problem that affects millions of people across the globe. Even though there are many available treatments, a significant number of people with depression don’t see an improvement with standard therapies. A more severe form of depression, known as treatment-resistant depression (TRD), is particularly hard to treat and can greatly impact a person’s quality of life. Recent research has hinted that therapy with the help of psilocybin, a psychedelic, could be a promising solution for TRD. Yet, the cost-effectiveness of this approach hasn’t been fully understood.

Psilocybin-assisted therapy is a form of mental health treatment that combines the use psilocybin, found naturally in certain types of so-called “magic” mushrooms, with psychological support or psychotherapy. Psilocybin-assisted therapy is a promising approach being studied for its potential benefits in treating conditions such as depression, anxiety, post-traumatic stress disorder, and addiction.

“Effective and relatively inexpensive treatments for depression exist, but a significant proportion of people with depression will have an inadequate treatment response and relapse rates can be high,” the authors of the new study wrote.

The researchers used a computer model to predict the cost-effectiveness of psilocybin-assisted therapy for TRD over the course of six months. The simulation was based on data from existing clinical studies and included various assumptions about the effectiveness and costs of psilocybin-assisted therapy. The model compared the costs and benefits (improvements in quality of life) of psilocybin-assisted therapy with those of conventional treatments for TRD, such as antidepressant medications and psychotherapy.

Over this six-month period, the researchers found that the highest increase in quality of life was for patients who received psilocybin-assisted therapy (a score of 0.310). This was followed by a combination of medication and cognitive-behavioral therapy (CBT) (0.287), then CBT alone (0.283), and finally medication alone (0.276).

The cost of psilocybin ranged from £400 to £2000 per person. The total expected healthcare costs for psilocybin therapy ranged from £6255 to £7775, which was higher compared to conventional medication alone (£3700), CBT alone (£4405), and a combination of medication and CBT (£4351).

The researchers found that the cost of therapist support was a major factor in the cost-effectiveness of psilocybin-assisted therapy. If the cost of therapist support was halved and the cost of psilocybin was below £800, then psilocybin-assisted therapy became more cost-effective compared to combined therapy, conventional medication alone, and CBT alone.

“While psilocybin and other psychedelic therapies have been identified as potentially useful treatment options, there are clear challenges in their application. Firstly, psychedelics (including psilocybin) are controlled substances under Schedule 1 of the [U.K.s’ Misuse of Drugs Act 1971] and approval for their use in research studies must be specifically obtained. This adds considerable costs at present that will reduce once/if they become approved medicines,” the researchers explained.

“Furthermore, it is recognised that support for patients is required prior to, during, and after the administration of psilocybin, which has large implications for cost-effectiveness. Our modelling study has indicated that if the level of support is at the higher end, then this adversely affects cost-effectiveness,” the researchers added. However, they said, in routine practice it is unlikely that psilocybin-assisted therapy would require 38 hours of a therapist’s time, which is what was provided in the clinical trials used for their models.

However, there are some caveats to this study. First, it relied on data from existing studies, which were limited and had short follow-up times. Second, the cost estimates were based on older studies, and the cost and effectiveness of treatments may have changed over time. Third, the study didn’t take into account possible negative effects of psychedelic-assisted therapy, which could impact its cost-effectiveness. Lastly, the study was based on healthcare costs in the UK, so other countries might have different costs that could affect the choice and success of therapy.

“This study provides preliminary information about the potential cost-effectiveness of psilocybin for treating severe depression,” the researchers concluded. “The results indicate positive findings from a societal perspective, which may identify and facilitate more cost-effective approaches to psilocybin therapy. It is essential to better understand who the drug should be prioritised for in terms of treatment resistance and how much therapist support is required.”

The study, “Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model,” was authored by Paul McCrone, Henry Fisher, Clare Knight, Rebecca Harding, Anne K. Schlag, David J. Nutt, and Joanna C. Neill.

TweetSendScanShareSendPinShareShareShareShareShare

RELATED

Some dark personality traits may help buffer against depression, new psychology research suggests
Mental Health

Psilocybin-assisted therapy linked to reduced depression in people with bipolar disorder, small study finds

June 17, 2025

A pilot study involving psilocybin-assisted therapy found possible antidepressant effects for people with bipolar II disorder. The treatment appeared well-tolerated, with no signs of mania or psychosis, offering cautious optimism for future bipolar depression research.

Read moreDetails
Psilocybin from “magic” mushrooms weakens the brain’s response to angry faces
Addiction

Single-dose psilocybin therapy shows promise for reducing alcohol consumption

June 15, 2025

Early results from a pilot study indicate that psilocybin-assisted therapy could be linked to lower alcohol consumption and improved psychological outcomes, though larger controlled trials are needed to determine whether the psilocybin itself is responsible for these changes.

Read moreDetails
Psilocybin appears to have a uniquely powerful relationship with nature relatedness
Neuroimaging

Psilocybin induces large-scale brain network reorganization, offering insights into the psychedelic state

June 14, 2025

A new study using high-resolution EEG reveals that psilocybin dramatically alters brain connectivity in rats. The psychedelic induced dose-dependent changes in network organization, disrupting normal patterns of neural communication and suggesting rodents may be viable models for studying altered consciousness.

Read moreDetails
Meta-analysis highlights potential of psilocybin therapy for treatment-resistant depression
Depression

Psilocybin therapy shows similar benefits for patients with and without recent antidepressant use

June 11, 2025

A new study finds that individuals with treatment-resistant depression experienced similar improvements from psilocybin-assisted psychotherapy whether or not they had recently discontinued antidepressant medications.

Read moreDetails
Single-dose psilocybin therapy shows promise for veterans with treatment-resistant depression
Psilocybin

21-year-old man dies after jabbing pencil into his brain during psilocybin trip

June 5, 2025

A detailed case report describes how a 21-year-old man died from self-inflicted ocular trauma during a bad psilocybin trip. The tragic event illustrates how rare but extreme reactions to psychedelics can lead to fatal outcomes.

Read moreDetails
Clinical psychologists appear to have cautiously favorable attitudes toward psychedelic-assisted mental health treatments
Psilocybin

Only a specific dose of psilocybin induces lasting antidepressant-like effects, study suggests

May 27, 2025

A recent study found that a single moderate dose of psilocybin produced lasting antidepressant-like effects in rats, while higher doses led to unwanted side effects. The findings highlight the importance of optimal dosing.

Read moreDetails
Psilocybin and escitalopram produce antidepressant effects via distinct brain mechanisms, study suggests
Depression

Psilocybin and escitalopram produce antidepressant effects via distinct brain mechanisms, study suggests

May 25, 2025

A new study using brain scans found that psilocybin and escitalopram reduce depression symptoms through different neural mechanisms. While escitalopram dampened emotional brain activity, psilocybin preserved or slightly increased it, suggesting distinct pathways to recovery.

Read moreDetails
Antidepressants may diminish psilocybin’s effects even after discontinuation
Depression

A single dose of psilocybin might help reduce symptoms in treatment-resistant depression

May 12, 2025

A new open-label study suggests that a single dose of psilocybin, combined with psychological support, may reduce symptoms in people with severe treatment-resistant depression. Improvements were sustained for up to 12 weeks, although effects were weaker in those with PTSD.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Neuroscientists shed new light on how heroin disrupts prefrontal brain function

New research identifies four distinct health pathways linked to Alzheimer’s disease

A surprising body part might provide key insights into schizophrenia risk

Religious belief linked to lower anxiety and better sleep in Israeli Druze study

A common vegetable may counteract brain changes linked to obesity

Massive psychology study reveals disturbing truths about Machiavellian leaders

Dementia: Your lifetime risk may be far greater than previously thought

Psychopathic tendencies may be associated with specific hormonal patterns

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy